ABUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Arbutus Biopharma's revenue for the three months ended in Sep. 2024 was $1.34 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $6.74 Mil. Arbutus Biopharma's Revenue per Share for the three months ended in Sep. 2024 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.04.
Warning Sign:
Arbutus Biopharma Corp revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Arbutus Biopharma was -72.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 8.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Arbutus Biopharma's highest 3-Year average Revenue per Share Growth Rate was 237.10% per year. The lowest was -69.70% per year. And the median was -1.30% per year.
The historical data trend for Arbutus Biopharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
6.01 | 6.91 | 10.99 | 39.02 | 18.14 |
Arbutus Biopharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
4.66 | 2.15 | 1.53 | 1.73 | 1.34 |
For the Biotechnology subindustry, Arbutus Biopharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Revenue distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (NAS:ABUS) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Arbutus Biopharma's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Karen Sims | officer: Chief Medical Officer | 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
David C Hastings | officer: Chief Financial Officer | C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
J. Christopher Naftzger | officer: General Counsel and CCO | 633 LOWTHER ROAD, LEWISBERRY PA 17339 |
Michael J. Mcelhaugh | officer: Chief Business Officer | C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902 |
Keith S Manchester | director | C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L |
Michael J. Sofia | officer: Chief Scientific Officer | C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
Melissa Rewolinski | director | 9000 STATE ROAD, PHILADELPHIA PA 19136 |
Tram Tran | director | C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
James R Meyers | director | GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Andrew Cheng | director | 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080 |
Myrtle S Potter | director | 10 FINDERNE AVE, BRIDGEWATER NJ 08807 |
William H. Collier | director, officer: President and CEO | C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
Elizabeth Howard | officer: Executive VP & General Counsel | 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
From GuruFocus
By Marketwired • 11-15-2024
By GuruFocus News • 11-06-2024
By GuruFocus Research • 08-02-2024
By GuruFocus News • 11-07-2024
By Marketwired • 11-06-2024
By Marketwired • 11-26-2024
By Marketwired • 05-22-2024
By GuruFocus Research • 05-02-2024
By GuruFocus News • 11-07-2024
By Marketwired • 05-29-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.